Vivos Inc. (RDGL)
OQB · Healthcare · Medical Devices
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Vivos Inc.
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 15K | 2K | 25K | 36K |
| Gross Profit | -35K | -13K | -3K | -8K |
| Operating Income | -675K | -531K | -1.1M | -545K |
| Net Income | -646K | -507K | -1.1M | -1.2M |
| Diluted EPS | $0.00 | $0.00 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 36K | 20K | 28K | 68K |
| Gross Profit | 8K | -6K | -3K | -60K |
| Operating Income | -2.5M | -2.8M | -2.6M | -3.2M |
| Net Income | -2.5M | -2.9M | -2.9M | -3.1M |
| Diluted EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 |